A dose-response evaluation of ALK tree AIT
Phase of Trial: Phase II
Latest Information Update: 20 Jan 2014
At a glance
- Drugs Birch pollen allergy immunotherapy (Primary)
- Indications Allergic rhinoconjunctivitis
- Focus Adverse reactions; Therapeutic Use
- 08 Nov 2013 Status changed from active, no longer recruiting to completed, according to a media release.
- 15 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 29 Aug 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health, NCT01675791).